Navigation Links
Pseudomonas putida

Multiporator / Electroporator 2510 Transformation Protocol Protocol No. 4308 915.529 01/2002 Microorganism Pseudomonas putida P8 Cell type Bacteria, gram negative Molecules injected Plasmid DNA Growth medium Standard 1-medium Washing solution 10% glycerol Electroporation solution 10% glycerol Outgrowth medium Standard 1-medium Cuvette 2 mm gap width Reference Prof. Friedhelm Meinhardt Universitt Mnster Corrensstrae 3 D-48149 Mnster
e-mail: meinhar@uni-muenster.de Making electrocompetent cells:

1. Inoculate 50 ml standard-1 medium with 7 ml of a fresh overnight culture of Pseudomonas putida. Grow cells at 30 C to a density of O.D. of 0.8. 2. Harvest by centrifugation. 3. Wash twice with 50 ml ice-cold glycerol, centrifuge. 4. Resuspend cells in 0.8 ml ice-cold glycerol, keep on ice.

Electroporation of cells:

  1. Add 4 l plasmid DNA (1 g) to 40 l of electrocompetent cells. Homogenize by gently mixing with pipette several
    times. Transfer mixture into a prechilled cuvette.
  2. Wipe moisture from the cuvette and insert the cuvette into the device.
  3. Electroporation:

    Mode Prokaryotes O Voltage (V) 2,400 V Time constant (T) 5 ms
  4. Immediately add 1 ml standard 1-medium. Incubate 2 hours at 30 C.
  5. Plate cells on selective plates.
Expected Results: Transformation efficiency up to 2 x 104 transformants/g of DNA.


'"/>

Source:


Page: All 1 2

Related biology technology :

1. Pseudomonas aeruginosa
2. Pseudomonas putida
3. Pseudomonas aeruginosa
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
(Date:2/16/2017)... 16, 2017  ArmaGen, Inc., a privately held ... treat severe neurological disorders, today reported preliminary evidence ... the company,s investigational therapy for the treatment of ... type I, or MPS I). The initial results ... presented today at the 13 th annual ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
Breaking Biology News(10 mins):